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Despite enormous advances in
medicine in the 20th century,
diseases caused by
microorganisms still represent the
highest single cause of mortality
worldwide. The majority of deaths
are in developing countries but
industrialized countries also suffer
frequent outbreaks of diseases
caused by bacteria and fungi. The
problems are exacerbated by the
appearance of bacterial strains
with increased virulence or
enhanced resistance to antibiotics.
A staggering 98% of gonococcal
isolates in South-East Asia show
multidrug resistance and it has
been estimated that penicillin
resistance in Streptococcus
pneumoniae in the USA is at least
40%. Over 50% of hospital-
acquired infections in industrialized
countries are caused by drug-
resistant microorganisms.
As Miguel Vicente of the Centro
Nacional de Biotecnologia CSIS in
Madrid says, “Large-scale use of
antibiotics leads to greatly
increased resistance to them. We
can only hope to stay on top of
bacteria by continuing to develop
new weapons: new treatment
possibilities and new drugs. Yet
the number of new antibiotics
licensed for use in humans is
increasing more slowly than ever
before.” It is clear that a new
approach toward the development
of antimicrobial agents is required.
One possibility is offered by the
intense efforts that have been
initiated in the past decade to learn
more about the genetics of
microbes. Well over 100 bacterial
genomes have already been fully
sequenced and work on
sequencing several hundred more
is underway. The resulting
sequence information represents a
vast resource for the rational
design of drugs.
Genomics research is already
being used as a tool for identifying
potential new targets for
antibiotics. As an example,
comparative genomics can reveal
which genes are shared between
different pathogenic
microorganisms (while being
absent from man). Such genes
could represent targets for broad-
spectrum antibiotics. Recent
research on the genomes of three
important human pathogens,
Haemophilus influenzae,
Streptococcus pneumoniae and
Staphylococcus aureus, has
identified over 350 bacterial genes
that are common to these
organisms. Further work is required
to assess whether inhibition of the
genes would inactivate the
pathogens and to develop
inhibitors but the technique’s
potential is enormous. And
genomics could do much more, for
example, by providing information
about how microorganisms behave
during infection or upon challenge
with antibiotics it can suggest
more indirect ways of treatment.
It is no longer realistic to expect
new antibiotics to appear through
serendipity. As Vicente notes, “The
antibiotics that were ‘easy’ to
discover are already well known.
The identification of new antibiotics
will require a large amount of high-
quality, i.e., high-cost, research.” In
recognition of this, the US
Department of Energy established
its Microbial Genome Program as
long ago as 1994. In 1996 the
Japanese program ‘Genome
Microbiology’ was initiated, with a
major emphasis on genomic
studies of pathogenic
microorganisms. In 1998 all EU
member states agreed that
combating resistance to
antimicrobial agents required a
common European strategy.
There is a widespread belief
among medical researchers that
the development of new drugs is of
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pressing importance but it appears
that not all clinicians share this
view. Vicente and his colleague
Jesús Blázquez, together with
Orietta Massidda of the University
of Cagliari, recently undertook a
survey of medical professionals
working in Madrid and Cagliari and
were surprised to learn that only
about a third of them thought that
the discovery of new antibiotics
was urgently required. The others
were satisfied that most ‘normal’
cases can be treated with one or a
few available drugs. Statistically,
this belief may be justified but in
cases involving elderly or
immunocompromised patients the
prognosis is often significantly
poorer and especially for these
people the development of new
treatments is a matter of priority.
Governments in Europe have
been slow to dedicate research
money to the area and European
funding in the subject remains
rather fragmented and
unstructured. Only a few specific
research funding programmes
exist and in most European
countries the area is treated as a
partial activity within a more
comprehensive biotechnology or
genome research program or is
funded purely on an ad hoc basis.
In response to the problem the
EU’s Sixth Framework Program for
Research and Technological
Development includes a specific
program for ‘Integrating and
Strengthening the European
Research Area (ERA)’. Within this,
the so-called ERA-NET scheme
has been initiated with the aim of
improving coordination and
cooperation of national and
regional programmes, thereby
pooling research resources and
maximizing efficiency throughout
the European Union.
ERA-NETs are awarded in a
‘bottom-up’ manner following an
open call for proposals in any field
of science and technology. The
participants in ERA-NETs are
national and regional program
makers and managers and funding
is used for coordination activities
rather than research itself.
Nevertheless, the scheme has
been welcomed by researchers,
who recognize that national
funding alone does not enable
them to do as much as they would
like and who are often frustrated to
see their research duplicated in
other countries.
Of the initial round of ERA-NET
proposals, thirty-two were
approved for funding. Although
each of the resulting projects
focuses on a different scientific
area, the overall goals of all ERA-
NETs are highly similar. In a first
step a thorough survey of national
and international funding activities
in the relevant subject area is
undertaken. This analysis of the
status quo is designed to provide
the information required to enable
future research activities to be
coordinated across national
borders. Subsequent work
identifies the areas in which
transnational cooperation would
be most beneficial and attempts to
identify opportunities for countries
to work together. Attention is also
paid to countries outside the EU,
such as the USA, Japan and China.
ERA-NETs provide opportunities
for workshops and exchange
programmes to offer training and
mobility support for junior
researchers. Finally and perhaps
most importantly, each ERA-NET
should implement one or more
joint activities, such as a common
call for research proposals. The
ultimate hope is that ERA-NETs will
pave the way for new transnational
funding mechanisms that will
enable national systems
collectively to take on tasks that
they would not have been able to
tackle independently.
The importance of coordinating
genomic research on disease-
causing microorganisms made the
topic a clear choice for the ERA-
NET scheme. A group of science
ministries and funding agencies
from ten countries — Austria,
Finland, France, Germany,
Hungary, Israel, Latvia, Portugal,
Slovenia and Spain — thus joined
forces to request funding for such
an initiative. Further organizations
from Great Britain, Lithuania,
Malta, the Netherlands, Norway
and Sweden were involved as
“affiliated partners”. The proposal
was extremely positively evaluated
and in September the ERA-NET
PathoGenoMics was officially
launched.
PathoGenoMics now provides a
framework for these fifteen
countries to work together for the
next five years. The program’s
coordinator, Wilfried Diekmann of
the Research Center Jülich,
Germany, sees the ERA-NET as a
wonderful opportunity. “Germany
already has a research
programme in the area... and we
hope that our experience will be
useful to our new partners. We are
confident that, with their help, we
shall manage to contribute to the
development of a European
research strategy in the area. All
of us stand to gain enormously
from the programme.”
A further aim of PathoGenoMics
is to enhance public awareness of
the need for the development of
new therapeutic possibilities
against pathogenic bacteria. To
this end the programme includes
a work-package designated
‘Science and Society’, to be
coordinated by Benny Leshem
from the Israeli Ministry of Health.
“now is the time to show the
public what has been done with
public funds and to make people
understand how vital it is for
everybody that we improve our
research into the organisms that
cause disease.” Vicente adds,
“We are all talking about the cost
of the research... many clinical
tests are required before drugs
are approved and companies are
sometimes reluctant to invest in
research to produce something
that cures diseases when the
alternative is a medicine that must
be taken daily and so brings them
far greater profits,” he says. “But
it is important to remember that
the current high prevalence of
resistance to ‘standard’
antibiotics is forcing us to use
exotic treatments that are many
times more expensive. The
availability of new and better
antimicrobial agents would lead to
a dramatic reduction in the cost of
health care.”
As Philippe Glaser, a scientist at
the Institut Pasteur in Paris and a
member of the PathoGenomMics
executing board puts it,
“Genomics and post-genomics
offer efficient methods to improve
our understanding of pathogenic
microorganisms and thus to
contribute to the development of
more and better methods to
combat them.”
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